Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report

Area of Science:

• Oncology
• Immunology
• Cardiology

Background:

• PD-1/PD-L1 inhibitors are crucial cancer therapies activating immune responses.
• Immune-related adverse events (irAEs), including cardiotoxicity, can occur.
• Immune-related cardiotoxicity is rare but potentially fatal.

Observation:

• A male patient developed cardiotoxicity one year after pembrolizumab treatment.
• Initial symptoms were atypical, followed by rapid deterioration and severe cardiac disease.
• Corticosteroid treatment provided initial relief, but the event recurred upon discontinuation.

Findings:

• Recurrent cardiotoxicity was ultimately resolved with higher doses and longer corticosteroid courses.
• Cardiac lesions remained stable for an extended period after pembrolizumab cessation.
• Pembrolizumab was discontinued for eight months with sustained lesion stability.

Implications:

• Corticosteroids are effective in managing severe immunotherapy-related cardiotoxicity.
• Long-term monitoring and management strategies are crucial for patients on PD-1/PD-L1 inhibitors.
• Understanding and treating irAEs is vital for optimizing cancer immunotherapy outcomes.